Medical-device giant Medtronic (MDT) beat analysts’ quarterly estimates and affirmed its guidance Thursday, sending its stock up as much as 1.3% in early trading. Medtronic reported fiscal Q1 earnings, excluding one-time items, of $1.02 a share in the quarter ended July 31, up 3% from the year-earlier quarter and a penny over views. Revenue totaled $7.27 billion, up 70% from last year’s Q1, or 12% if you include the recently acquired Covidien in
Medtronic (MDT) stock got a lift Wednesday, a day ahead of its scheduled fiscal Q1 earnings report, as an analyst raised his price target on the medical device giant’s shares. Cowen and Co. analyst Joshua Jennings wrote in a research note Wednesday that Medtronic — which acquired Covidien this year — should generate “top tier” growth in both earnings and revenue. He said that relocating the official Medtronic headquarters to Covidien’s hometown of
Medical-device giant Medtronic (MDT) released preliminary fiscal Q4 earnings Tuesday that were above expectations, but it warned that its outlook will be battered by foreign-exchange headwinds. Medtronic was up more than 1% in early trading in the stock market today , near 78.50. Medtronic stock touched an all-time high of 79.50 on March 25. Medtronic said sales in the quarter ended April 24 totaled $7.3 billion, topping analysts’ consensus of